Results 171 to 180 of about 969,782 (213)
Some of the next articles are maybe not open access.
Combining molecular targeted therapies
Anti-Cancer Drugs, 2011Approximately 20 molecular targeted therapies, mainly monoclonal antibodies and tyrosine kinase inhibitors, have been approved for the treatment of various cancers. They are being increasingly investigated in combination in clinical trials. We review the rationale for combining molecular targeted therapies and the results of clinical trials to date ...
Xavier, Pivot +4 more
openaire +2 more sources
Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry, 2008Malignant mesothelioma is a highly invasive tumor originating from the mesothelial linings of the pleura, peritoneum and pericardium. It is seldom amenable to surgical intervention and poorly responsive to radiotherapy, leaving chemotherapy as the main therapeutic option for most patients. The development of effective drug regimens against mesothelioma
PALUMBO, CAMILLA +3 more
openaire +3 more sources
[Molecular targeted therapies].
Nihon rinsho. Japanese journal of clinical medicine, 2010Current treatment paradigms in cancer patients are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. Targeted therapies are entering standard treatment paradigms. As patient responses to targeted therapies vary, predictive biomarkers will be an important tool of a patient's diagnostic workup
Hideharu, Kimura, Kazuto, Nishio
openaire +1 more source
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2007
Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration.
F, Stenner-Liewen +3 more
openaire +1 more source
Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration.
F, Stenner-Liewen +3 more
openaire +1 more source
Molecular targets in cancer therapy
Seminars in Oncology Nursing, 2003To review selected pharmacologic agents that target key cellular processes along with their mechanisms of action and adverse events. Nursing implications including what patients and families need to know, administration issues, and management of common toxicities will be reviewed.Research articles, clinical trials, abstracts, and book chapters ...
openaire +2 more sources
Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design, 2004The dysfunction or proliferation of lymphatic vessels (lymphangiogenesis) is linked to a number of pathological conditions including lymphedema and cancer. The recent discovery and characterisation of the lymphangiogenic growth factors vascular endothelial growth factor-C (VEGF-C) and VEGF-D and of their receptor on lymphatic endothelial cells, VEGFR-3,
S A, Stacker, R A, Hughes, M G, Achen
openaire +2 more sources
Targeted molecular therapy of malignant gliomas
Current Neurology and Neuroscience Reports, 2005Malignant gliomas are the most common form of primary brain tumors in adults. Despite advances in diagnosis and standard therapies such as surgery, radiation, and chemotherapy, the prognosis remains poor. Recent scientific advances have enhanced our understanding of the biology of gliomas and the role of tyrosine kinase receptors and signal ...
Santosh, Kesari +4 more
openaire +3 more sources
Molecular Targeted Therapies in Hepatocellular Carcinoma
Seminars in Oncology, 2012In vivo tumor progression requires the supply of oxygen and nutrition by neovasculature. Hepatocellular carcinoma (HCC) is one of the typical tumors with neovascularization, and the dramatic alteration in the arterial vascularity may lead to acquisition of the potential for vascular invasiveness and metastasis.
Shinji, Tanaka, Shigeki, Arii
openaire +2 more sources
2017
Defining potential molecular targets for sepsis therapeutics has proven to be a real challenge in translating laboratory findings into effective clinical treatments. A myriad of possible targets have been proposed from preclinical studies but they often have overlapping pathologic functions, can differ depending upon the causative microbial pathogen ...
Andre C. Kalil, Steven M. Opal
openaire +1 more source
Defining potential molecular targets for sepsis therapeutics has proven to be a real challenge in translating laboratory findings into effective clinical treatments. A myriad of possible targets have been proposed from preclinical studies but they often have overlapping pathologic functions, can differ depending upon the causative microbial pathogen ...
Andre C. Kalil, Steven M. Opal
openaire +1 more source
Molecular-targeted therapy in malignant melanoma
Expert Review of Anticancer Therapy, 2009Malignant melanoma is a deadly disease in which standard treatment options have remained remarkably static over the past 30 years. Recent discoveries have expanded the understanding of the molecular processes critical to melanomagenesis. During this same time period, therapeutic agents have been developed that target these processes, leading to an ...
Ryan J, Sullivan, Michael B, Atkins
openaire +2 more sources